MilliporeSigma doubles viral vector production with new facility

By The Science Advisory Board staff writers

October 12, 2021 -- MilliporeSigma has opened a second contract development manufacturing facility in California to focus on viral vector technologies for cell and gene therapy.

MilliporeSigma is opening a second Carlsbad, CA-based facility.
MilliporeSigma is opening a second Carlsbad, CA-based facility that will more than double the company's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.

The $110 million, 140,000-sq-ft facility in Carlsbad -- the firm's second in the city -- will more than double MilliporeSigma's production capability for large-scale commercial and industrial manufacturing for viral gene therapy. This capacity increase will help its customers bring new gene therapies to markets for larger patient populations, the company said.

"We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients," said Matthias Heinzel, CEO of Life Science at Merck KGaA, in a statement. MilliporeSigma is the U.S. and Canadian life sciences division of Merck KGaA.

There are 30 cleanroom suites between the two manufacturing facilities in Carlsbad, CA, to support all aspects of manufacturing, ranging from small- to large-scale clinical and commercial production, according to MilliporeSigma. The company noted that the new facility utilizes suspension technology that can produce viral vectors up to the 1,000-liter scale.

MilliporeSigma scales up lipid production for COVID-19 vaccines
MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA-based...
MilliporeSigma boosts capacity at French assembly facility
MilliporeSigma is adding a single-use assembly production unit to its facility in Molsheim, France.
MilliporeSigma acquires AmpTec
MilliporeSigma has purchased messenger RNA firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture messenger RNA...
MilliporeSigma invests $47M in U.S. biomanufacturing facilities
MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing...
MilliporeSigma holds topping-out ceremony for new membrane plant
MilliporeSigma celebrated the topping out of its new membrane production plant in Darmstadt, Germany, with a ceremony on October 8.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter